A Case Analysis of Antiplatelet Therapy in a Patient with Acute Coronary Syndrome after PCI

通过对经皮冠状动脉介入治疗(PCI)术后抗血小板治疗方案进行分析，为临床个体化用药提供参考。通过查阅近几年国内外相关指南及文献，基于本案例分析抗血小板治疗方案。该患者PCI术后给予口服阿司匹林与替格瑞洛双重抗血小板治疗后未有临床不良事件结果的发生，说明该患者治疗方案是合理的。PCI术后治疗的关键是抗血小板治疗，临床药师通过参与该疾病临床路径的药物治疗，根据患者的具体情况结合药物特性协助医生为患者制订个体化用药方案。在此案例中，临床药师查阅相关文献，通过参与会诊，临床查房，电话随访等手段，积极开展药学监护与用药指导，提高患者用药安全性、有效性与依从性，促进临床合理用药，改善和提高患者生活质量。Objective(s): By analyzing the antiplatelet therapy regimen after percutaneous coronary intervention (PCI), it can provide reference in recent years, the antiplatelet therapy regimen was analyzed based on this case. Results: After PCI, the patient was given oral aspirin and ticagrelor dual antiplatelet therapy, and no clinical adverse events occurred, indicating that the patient’s treatment plan was reasonable. Conclusion(s): The key to post-PCI treatment is antiplatelet therapy. By participating in the drug treatment of the clinical pathway of the disease, clinical pharmacists assist doctors to formulate individualized drug regimens for patients according to the specific conditions of patients and the characteristics of drugs. In this case, pharmaceutical care and medication guidance were actively conducted through literature review, multidisciplinary consultation participation, clinical ward rounds, and telephone follow-up by clinical pharmacists. Safety, effectiveness, and compliance of patient medication were enhanced. Clinical rational drug use was promoted. Patient quality of life was improved.